NCT02260193 - 16-Week Repeat Oral Dose Study of AKB-6548 for Anemia in Participants With End Stage Renal Disease (ESRD) Requiring Chronic Hemodialysis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 10, 2014

Primary Completion Date

July 22, 2015

Study Completion Date

July 22, 2015

Conditions

AnemiaEnd Stage Renal Disease

Interventions

DRUG

AKB-6548

Starting dose 1. Oral dose administered once daily for 16 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.

DRUG

AKB-6548

Starting dose 2. Oral dose administered once daily for 16 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.

DRUG

AKB-6548

Starting dose 3. Oral dose administered three times weekly for 16 weeks. Dose adjustment based on hemoglobin levels as defined in the protocol.

Trial Locations (16)

El Granada

Long Beach

San Dimas

Santa Clarita

Whittier

Arvada

Westminster

Naples

North Miami Beach

Augusta

Astoria

Arlington

Grand Prairie

Greenville

Houston

Mechanicsville